Method Article

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

DOI:

10.3791/53570

December 1st, 2017

* These authors contributed equally

In This Article

Summary

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Periventricular nodular heterotopia (PNH) is the most common form of malformation of cortical development (MCD) in adulthood but its genetic basis remains unknown in most sporadic cases. We have recently developed a strategy to identify novel candidate genes for MCDs and to directly confirm their causative role in vivo.

Abstract

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Birth defects that involve the cerebral cortex — also known as malformations of cortical development (MCD) — are important causes of intellectual disability and account for 20-40% of drug-resistant epilepsy in childhood. High-resolution brain imaging has facilitated in vivo identification of a large group of MCD phenotypes. Despite the advances in brain imaging, genomic analysis and generation of animal models, a straightforward workflow to systematically prioritize candidate genes and to test functional effects of putative mutations is missing. To overcome this problem, an experimental strategy enabling the identification of novel causative genes for MCD was developed and validated. This strategy is based on identifying candidate genomic regions or genes via array-CGH or whole-exome sequencing and characterizing the effects of their inactivation or of overexpression of specific mutations in developing rodent brains via in utero electroporation. This approach led to the identification of the C6orf70 gene, encoding for a putative vesicular protein, to the pathogenesis of periventricular nodular heterotopia, a MCD caused by defective neuronal migration.

Introduction

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The cerebral cortex plays a key role in cognitive and intellectual processes and is involved in emotional control as well as learning and memory. It is therefore not surprising that many neurological and psychiatric diseases result from malformations of cortical development (MCD). The etiology of MCD is complex since both acquired and genetic factors are involved. The cumulative prevalence of genetically determined proportion of MCD is about 2% and they are sporadic in most cases. For instance, the incidence of congenital brain dysgenesis was estimated to be higher than 1% in the human population, and some forms of MCD are observed in more than 14% of all patients with epilepsy and in 40% of severe or intractable epilepsy1,2.

Periventricular Nodular Heterotopia (PNH) is one of the most common MCDs and is caused by abnormal migration of neurons from the ventricular zone (VZ) to the developing cerebral cortex. The failure of neurons to migrate results in clusters of heterotopic neurons along the walls of the lateral ventricles which can usually be visualized using Magnetic Resonance Imaging (MRI). The clinical, anatomic and imaging features of PNH are heterogeneous. Nodules may range from small and unilateral to bilateral and symmetric. Common clinical sequelae include epilepsy and intellectual disabilities3. Mutations in the Filamin A (or FLNA) gene, which maps in Xq28, were found in 100% of families with X-linked bilateral PNH and in 26% of sporadic patients3,4. A rare, recessive form of PNH caused by mutations in the ARFGEF2 gene, which maps in 20q13, has been reported in two consanguineous families5. Recently, biallelic mutations in genes encoding the receptor-ligand cadherin pair DCHS1 and FAT4 have been identified in nine patients affected by a multisystemic disorder that includes PNH6. PNH has also been associated with fragile X syndrome7, Williams syndrome8, 22q11 microdeletion syndrome9, duplications at 5p1510, deletions at 1p3611, 5q14.3-q1512, 6p2513 and 6q terminal deletion syndrome14,15,16,17,18,19, suggesting that additional causative genes are scattered throughout the genome. However, for approximately 74% of sporadic PNH patients the genetic basis remains to be elucidated17.

Classical gene mapping approaches such as array Comparative Genomic Hybridization (array-CGH) have proven to be a powerful tools for the detection of sub-microscopic chromosomal abnormalities, however, the genomic regions identified using this approach are often large and contain numerous genes.

The advent of massive parallel sequencing techniques (i.e. Whole-Exome Sequencing (WES) and Whole-Genome sequencing (WGS)) has substantially reduced both the cost and the time required to sequence an entire human exome or genome. Nevertheless, interpretation of WES and WGS data remains challenging in the majority of cases, since for each patient tens to hundreds (or even thousands, depending from the type of analysis) variants emerge from data filtering.

To speed up the process of identifying novel MCD causative genes, a novel systematic strategy combining array-CGH, WES and in utero electroporation (IUE) screening of candidate genes was designed. IUE allows to selectively inactivate (or overexpress) specific genes or mutations in rodent brains, enabling rapid evaluation of their involvement in corticogenesis18,19. RNAi mediated-knockdown or overexpression of one or more candidate genes is expected to cause, when the gene is associated with disease development, localized defects in neuronal migration and/or maturation. Upon the identification of a gene whose inactivation (or overexpression) reproduces the phenotype observed in patients in rodents, it becomes an outstanding candidate for the screening in sporadic patients with MCD. Using this approach, we recently revealed the crucial contribution of the C6orf70 gene (also known as ERMARD) in PNH pathogenesis in patients harbouring 6q27 chromosomal deletions16.

Access restricted. Please log in or start a trial to view this content.

Protocol

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

Ethics Statement: Wistar rats were mated, maintained and used in the INMED animal facilities, in agreement with European Union and French legislation.

1. DNA Extraction and Quantification for Array-CGH and WES

  1. Extract Genomic DNA (gDNA) from human blood leukocytes from patients using an automated DNA isolation robot or commercially available manual DNA extraction kits according to the manufacturer's protocol. Quantify all samples using a spectrophotometer.

2. Array-CGH Protocol

  1. Restriction Digestion of gDNA
    1. Double digest 500 ng of purified gDNA from a patient and a commercially available human control DNA with RsaI and AluI for 2 h at 37 °C. Use 0.5 μl of 10 U/μL enzyme for each reaction. Incubate for 20 min at 65 °C to inactivate the enzymes and move the sample tubes to ice.
  2. Sample Labelling
    1. Add the appropriate volume of Random Primers needed for the microarray format in use to each reaction tube (e.g. 5 µl for 1-pack, 2-pack, and 4-pack microarrays). Mix well by pipetting up and down gently.
    2. Transfer sample tubes to a thermal cycler. Incubate at 95 °C for 3 min and then at 4 °C for 5 min.
    3. Prepare one cyanine 3 and one cyanine 5 Labelling Master Mix on ice by mixing the following volumes: 10.0 µl 5X Reaction Buffer, 5.0 µl 10x dNTPs, 3.0 µl Cyanine 3-dUTP or Cyanine 5-dUTP and 1.0 µl Exo(-)Klenow enzyme, 2.0 µl Nuclease-Free Water. Choose the volume of each reagent according to the microarray format in use.
    4. Add the Labelling Master Mix to each reaction tube containing the gDNA. Mix well by gently pipetting up and down.
    5. Transfer sample tubes to a thermal cycler and incubate at 37 °C for 2 h, 65 °C for 10 min and then maintain the samples at 4 °C.
  3. Purification of labelled gDNA
    1. Add 430 µl of 1x TE (pH 8.0) to each reaction tube.
    2. Place a purification column into 2 mL collection tubes and label the columns appropriately. Load each labelled gDNA onto a purification column.
    3. Centrifuge for 10 min at 14,000 x g in a microcentrifuge at room temperature. Discard the flow-through and place the column back in the 2 ml collection tube.
    4. Add 480 µL of 1x TE (pH 8.0) to each column. Centrifuge for 10 min at 14,000 x g in a microcentrifuge at room temperature. Discard the flow-through.
    5. Invert the column into a fresh 2 mL collection tube and centrifuge for 1 min at 1,000 x g in a microcentrifuge at room temperature to collect purified sample.
    6. Bring the sample volume to that requested for the microarray format in use using a concentrator or adding 1x TE (pH 8.0). For example, for 1-pack microarray bring the volume to 80.5 µL. Incubate the sample on ice for 5 min and then pipette the solution up and down 10 times.
  4. Preparation of labelled gDNA for Hybridization
    1. Combine test and reference samples using the appropriate cyanine 5-labeled sample and cyanine 3-labeled sample in a fresh 1.5 mL RNase-free tube. For example, for 1-pack microarray ensure that the final volume is 158 µL. Choose the volume of each sample according to the microarray format in use.
    2. Use a spectrophotometer to measure yield, degree of labelling or specific activity by measuring the absorbance at A260 nm (DNA), A550 nm (cyanine 3), and A650 nm (cyanine 5).
      1. Calculate yield using the formula: [DNA concentration(ng/µl) x sample volume (µl)]/1,000 (ng/µg). Calculate Specific Activity using the formula: pmol per µl of dye/µg per µl of gDNA.
        NOTE: For example, for 0.5 µg of input DNA, the yield should be 8 to 11 µg and the specific activity (pmol/µg) should be 25 to 40 for the Cyanine-3 labelled sample and 20 to 35 for the Cyanine-5 labelled sample.
    3. To prepare the amount of Hybridization Master Mix needed for the microarray format in use, mix the following reagents: 50 µL Cot-1 DNA (1.0 mg/ml), 52 µL 10x aCGH Blocking Agent and 260 µl 2x HI-RPM Hybridization Buffer.
    4. Add the appropriate volume of the Hybridization Master Mix to the 1.5 ml RNase-free tube that contains the labelled gDNA to obtain the total volume required for the microarray format in use. For example, for 1 pack microarray, ensure that the final volume for each reaction is 362 µl.
    5. Mix the sample by pipetting up and down, then quickly centrifuge at 14,000 x g and incubate for 3 min at 95 °C and at 37 °C for 30 min.
  5. Chambers assembly and Hybridization
    1. Load a clean gasket slide into the chamber base with the gasket label facing up and aligned with the rectangular section of the chamber base. Ensure that the gasket slide is flush with the chamber base and is not ajar.
    2. Dispense hybridization sample mixture onto the gasket well, making sure that the sample is uniformly distributed.
    3. Put a microarray slide down onto the gasket slide assessing that the sandwich-pair is properly aligned. Then, assemble the reaction chamber putting the cover onto the sandwiched slides and hand-tightening the clamp.
    4. Ensure slides wetting by rotating the assembled chamber vertically. Make sure that bubbles are not present in the chamber. If necessary, tap the assembly on a hard surface to move stationary bubbles.
    5. Put the assembled slide chambers in a rotator rack set up to rotate at 20 rpm. Put the hybridization chamber in an oven and perform the hybridization at 65 °C for 24 or 40 h according to the microarray format in use.
  6. Microarray washing and scanning
    1. Take hybridization chamber out of oven and submerge it in wash buffer 1. Proceed to its disassembly.
    2. Remove the microarray slide and quickly put it into a slide rack in wash buffer 1 at room temperature.
    3. Wash the array slide for 5 min with stirring (use a flea and a magnetic stirrer). Adjust the stirrer speed to a setting of 4 (medium speed), to get good but not too vigorous mixing.
    4. Wash the array slide in wash buffer 2 for 90 s stirring. Gently recover the slide from the buffer (it should emerge dry) and load it into a slide holder with the aid of a slide protector.
    5. Load the slide into the array scanner and perform scanning according to the array manufacturer's instructions.
    6. Analyze the results using the Extraction software provided with the scanner in use according to manufacturer's instructions (V.9.1.3.1).

3. WES Protocol

  1. Target enrichment
    1. Use the dsDNA BR Assay to determine the concentration of the gDNA sample according to the instrument protocol.
    2. Dilute 5 µg of high-quality double strand DNA with 1x Low TE buffer in a 1.5 mL low bind tube in a total volume of 50 µL.
    3. Set up a sonicator and put a microtube into the loading and unloading station according to the manufacturer's instruction. Keep the cap on the tube.
    4. Slowly transfer the 50 µl DNA sample through the pre-split septa without introducing bubbles.
    5. Shear the DNA according to the settings suggested from the sonicator's manufacturer and assess quality using a Bioanalyzer according to the manufacturer's instruction. The target DNA fragment size is 150 to 200 bp.
  2. Repair of DNA ends
    1. Prepare the End Repair Reaction Mix by mixing 40 µL of End Repair Enzyme Mix with 10 µL of End Repair Oligo Mix. Mix well on a vortex mixer.
    2. Incubate the samples at 20 °C for 30 min in a thermal cycler and then hold them at 4 °C. Do not use a heated lid.
    3. Add 50 µL of the End Repair Reaction Mix prepared in step 3.2.1 to each 50 µL sheared DNA sample well. Mix well by pipetting up and down or by gentle vortexing.
    4. Purify sample with a beads based purification kit according to manufacturer protocol.
  3. Polyadenylation of 3' ends.
    1. Add 20 µl of dA-Tailing Master Mix to each end-repaired, purified DNA sample (approximately 20 µL).
    2. Mix well by pipetting up and down or by gentle vortexing.
    3. Incubate the samples at 37 °C in a thermal cycler and then hold it at 4 °C. Do not use a heated lid.
  4. Ligation of the pre-capture indexing adaptor.
    1. Add 5 µL of Ligation Master Mix to each A-tailed DNA sample.
    2. Add 5 µL of the appropriate pre-capture Index solution to each sample.
    3. Seal the wells and mix thoroughly by vortexing for 5 s. Briefly centrifuge the samples.
    4. Incubate the samples at 20 °C for 15 min in a thermal cycler and then hold at 4 °C. Do not use a heated lid.
    5. Purify the samples with a beads based purification kit according to manufacturer protocol.
  5. Amplification of the indexed library.
    1. Prepare the appropriate volume of pre-capture PCR reaction mix by mixing 1 µL of Primer Mix and 25 µL of PCR Master Mix. Mix well on a vortex mixer.
    2. Combine 26 µL of the amplification mixture in separate wells of a PCR plate and 24 µL of each indexed gDNA library sample.
    3. Run a PCR program with the following steps: 98 °C for 2 min, 5 cycles at 98 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min and a final extension at 72 °C for 10 min. Hold the samples at 4 °C.
    4. Purify sample with a beads based purification kit according to manufacturer protocol.
    5. Assess quality with a Bioanalyzer according to manufacturer protocol.
  6. Pooling of indexed DNA samples for hybridization
    1. For each capture reaction pool, combine the appropriate volume of each indexed gDNA library sample in one well of a PCR plate. For example, for Human or Mouse All-Exon Capture Libraries, combine 8 libraries per pool using 187.5 ng of each indexed library. Ensure that each final capture reaction pool contains 1,500 ng of indexed gDNA.
    2. Reduce the volume in each well to <7 µL using a vacuum concentrator. Avoid completely drying the sample.
    3. Add sufficient nuclease-free water to each concentrated gDNA pool to bring the final well volume to 7 µL and then vortex the plate containing gDNA vigorously for 30 s. Centrifuge in a centrifuge or mini-plate spinner to collect the liquid at the bottom of the wells.
  7. Hybridization of gDNA library pools to the Capture Library
    1. To each 7 µL indexed gDNA pool, add 9 µl of blocking Mix. Pipette up and down to mix.
    2. Cap the wells, transfer the sealed plate containing gDNA to the thermal cycler and incubate at 95 °C for 5 min, then hold it at 65 °C. Make sure that the plate is held at 65 °C for at least 5 min.
    3. Prepare the appropriate dilution of RNase Block, on the basis of the size of the capture library (10% dilution for libraries < 3.0 Mb and 25% dilution for libraries >3.0 Mb).
    4. According to the Capture Library Size, combine the proper amount of Capture Library and dilute RNase Block solution in a PCR plate kept on ice. Mix well by pipetting. For capture libraries <3.0 Mb, use 2 µl of Library and 5 µL of RNase Block at 10% dilution. For capture libraries >3.0 Mb, use 5 µl of Library and 2 µl of RNase Block at 25% dilution.
    5. Add 37 µL of Hybridization Buffer to each well containing 7 µL of Capture Library/RNase Block mix. Mix well by pipetting and briefly centrifuge the plate containing the mix.
    6. Maintain the gDNA pool plate at 65 °C while using a multi-channel pipette to transfer the entire 44 µL of Capture Library mixture from step 3.7.5 to each sample well of the gDNA pool plate. Mix well by slowly pipetting up and down 8 to 10 times.
    7. Seal the wells with domed strip caps. Make sure that all wells are completely sealed. Place a compression mat over the PCR plate in the thermal cycler.
    8. Incubate the hybridization mixture for 24 h at 65 °C. Note: Samples may be hybridized for up to 72 h, but must verify that the extended hybridization does not cause extensive evaporation in the sample wells.
  8. Preparation of streptavidin-coated magnetic beads
    1. Prewarm Wash buffer 2 at 65 °C in a water bath or heat block.
    2. Vigorously resuspend the Streptavidin magnetic beads on a vortex mixer. The magnetic beads settle during storage.
    3. For each hybridization sample, add 50 µL of the resuspended beads to wells of a PCR plate.
    4. Wash the beads and resuspend them in 200 µL of Binding Buffer.
  9. Capture of the hybridized DNA using streptavidin beads.
    1. Estimate and record the volume of hybridization solution that remains after the 24 h incubation.
    2. Maintain the hybridization plate at 65 °C and use a multichannel pipette to transfer the entire volume (approximately 60 µL) of each hybridization mixture to the plate wells containing 200 µL of washed streptavidin beads. Mix well by slowly pipetting up and down 3 to 5 times.
    3. Cap the wells and incubate the capture plate on a Nutator mixer or equivalent for 30 min at room temperature. Make sure the samples are properly mixing in the wells.
    4. Briefly centrifuge the capture plate in a centrifuge or mini-plate spinner.
    5. Put the capture plate in a magnetic separator to collect the beads from the suspension. Remove and discard the supernatant.
    6. Resuspend the beads in 200 µL of Wash buffer 1. Mix by pipetting up and down until the beads are fully resuspended.
    7. Briefly centrifuge in a centrifuge or mini-plate spinner.
    8. Put the plate in the magnetic separator.
    9. Wait for the solution to clear, then remove and discard the supernatant.
  10. Post-capture Sample Processing for Multiplexed Sequencing
    1. Prepare the appropriate volume of PCR reaction mixture by mixing the following: 9 µL Nuclease-free water, 25 µL Master Mix and 1 µL Primer Mix according to the number of amplifications. Mix well using a vortex mixer and keep on ice.
    2. For each amplification reaction, place 35 µL of the PCR reaction mixture from step 3.10.1 in the wells of a PCR plate.
    3. Pipette each of the bead-bound captured library pool samples up and down to ensure that the bead suspension is homogeneous.
    4. Add 15 µL of each captured library pool bead suspension to the appropriate PCR reaction mixture well. Mix thoroughly by pipetting until the bead suspension is homogeneous.
    5. Place the plate prepared in point 3.10.2 in a thermal cycler and run the following PCR amplification program: 98 °C for 2 min, 8 to 11 cycles at 98 °C for 30 s, 60 °C for 30 s and 72 °C for 1 min, followed by a final extension at 72 °C for 10 min. Hold the samples at 4 °C.
    6. Purify sample with a beads based purification according to manufacturer protocol.
    7. Assess quality with a Bioanalyzer according to manufacturer protocol.
  11. Prepare samples for multiplexed sequencing
    NOTE: The final enriched samples contain pools of either 8 or 16 indexed libraries, based on the Capture Library size and resulting pre-capture pooling strategy. The total number of indexed libraries that may be multiplexed in a single sequencing lane is determined by the output specifications of the platform used, together with the amount of sequencing data required for the Capture Library.
    1. Calculate the number of indexes that can be combined per lane, according to the capacity of the platform. The total number of indexed libraries that may be multiplexed in a single sequencing lane is determined by the output specifications of the platform used, together with the amount of sequencing data required for the Capture Library. For example, for the Human All Exon v5 library, the Recommended Sequencing Data per Indexed Library is 4 Gb and the Recommended Sequencing Data per Pre-capture Pool is 32 Gb (8-index pools).
  12. Sequence the libraries.
    1. Load the libraries on the next generation sequencing platform of choice and perform the sequencing run according to the instrument specifications.
  13. Analyze exome sequencing data.
    1. Run the pipeline and the software of choice for base calling. For example, use Stampy to map reads20, remove duplicates with Picard (http://broadinstitute.github.io/picard/) and identify single nucleotide polymorphisms and insertion or deletion of bases (indels) with Platypus21. Filter synonymous variants and those observed at an allele frequency <5% and compare data with those from parental exomes to identify de novo variants.

4. Plasmid DNA Preparation for In Utero Electroporation

  1. Design several short hairpin RNAs (shRNAs) targeting either the coding sequence or the 3'UTR of the candidate genes as described previously22.
  2. To prevent off target effects test shRNAs specificity by BLAST search against databases using standard methods. Exclude shRNAs displaying more than 50% of complementarity with other rat genes.
  3. Clone annealed oligonucleotides into a mU6-pro vector as described previously23.
  4. Purify plasmid DNA with a Maxi-prep according to manufacturer's instructions and make a final concentration of 3 µg/µL.
  5. Aliquot 20 µl of DNA (0.5 mg/ml pCAGGS-GFP either alone or with 1.5 mg/ml of shRNA construct) and add 2 µL of Fast green dye (2 mg/mL) to allow visual monitoring of the injection.

5. In Utero Electroporation

  1. Surgical procedure
    1. Anesthetize E15.5 pregnant female rats (E0 was defined as the day of confirmation of sperm-positive vaginal plug), using a combination with a mixture of ketamine/xylazine (0.1 and 0.01 mg per body weight, respectively), which is given via an intraperitoneal injection for anesthetic induction.
    2. Make sure that the animal is fully anesthetized by observing the disappearance of toe pinch reflex.
    3. Shave the animal's lower abdomen using a clipper to remove the fur. Disinfect the skin using scrubs of povidone-iodine and 70% alcohol. Apply veterinarian ointment on eyes to prevent dryness while under anaesthesia.
    4. Place the animal on a heat source and put a sterile drape (with an open window of 4 - 5 cm in the middle) over the incision site. Wear facemasks, lab coat, caps, and sterile surgical gloves. Maintain sterility until the end of the surgery.
    5. Using sharp scissors to make a vertical incision (2 - 2.5 cm) in the skin along the midline in the caudal abdomen and then make an incision of the muscle wall underneath the skin — also of 2.5 cm — along the midline.
    6. Carefully expose one uterine horn from the abdominal cavity. Drop 37 °C pre-warmed normal saline solution to moisturize the embryos. Keep the uterus moist all the time.
  2. Injection of DNA and electroporation
    1. Gently hold one of the uterine horns with ringed forceps and carefully push one embryo to the uterine wall. Hold the embryo in one hand and with the other hand insert carefully glass capillaries 1 mm from the midline into the left lateral ventricle (2-3 mm deep) and inject approximately 1 µL of DNA with Fast Green to allow visual monitoring of the injection using a microinjector.
    2. Drop normal saline solution on the 3 x 7 mm2 electrodes surface. Place the positive sterile electrode on the injected side (left lateral ventricle) and the negative sterile electrode on the right ventricle. Deliver 5 electrical pulses at 950 ms intervals with a foot-controlled pedal (4000 mF capacitor charged to 40 V with an electroporator).
  3. Post electroporation procedures
    1. Put back uterine horns to the abdominal cavity, add drops of normal saline solution to the cavity to allow embryos positioned more naturally and to account for intraoperative fluid loss.
    2. Close the abdominal muscle wall with absorbable surgical sutures, then the skin using a simple-interrupted stitch.
    3. Put the rat back to the cage and monitor the animal until it emerges from the anaesthesia.
    4. For pain management administer buprenorphine (0.03 mg/kg) to the animal by a subcutaneous injection every 8 - 12 h, for up to 48 h.

6. Brain Sample Preparation

  1. Fixation method
    1. Sacrifice the pregnant rat 5 days after the surgical procedure using gas anaesthesia (isoflurane) followed by a quick cervical dislocation.
    2. Make a vertical incision to re-open the abdominal cavity.
    3. Expose the uterine horns, remove the embryos from the uterus and decapitate them using sharp scissors.
    4. Remove the brain with minimal damage to the tissue: using sharp scissors, make a small incision along the posterior (cerebellum) / anterior (olfactive bulbs) axis of the head to pierce the skin and the skull, then using a pair of forceps peel away the skull to expose the brain and remove it using a small spatula.
    5. Immerse brains overnight at 4 °C in a 4% Paraformaldehyde in 1x Phosphate Buffered Saline (PBS).
  2. Brain sectioning
    1. Wash brains in 1x PBS for 10 min.
    2. Embed brains in 4% agar in plastic embedding molds.
      1. Prepare 50 mL of 4% agar in 1x PBS for embedding 5 embryonic brains. Ensure that dissolved agarose is at no more than 50 °C.
    3. Keep brains in agarose to polymerize for at least 1 h at 4°C. Remove excess agarose around the brain.
    4. Glue the brain to the vibratome base plate, oriented so the anterior/posterior axis of the brain is perpendicular to the blade. Wait a few minutes for the glue to dry and place the plate with the glued brain into the vibratome chamber.
    5. Fill the vibratome with 1x PBS. Slice 100 µm thick sections.
    6. Transfer brain slices on slides, remove excess liquid, add a few drops of mounting medium and place a coverslip on top of brains

7. Confocal Imaging and Quantitative Analysis

  1. Let the mounting medium dry overnight before imaging. Image sections at 10X on a laser-scanning confocal microscope.
  2. Using software for quantitative image analysis, convert the image in 8-bit, select one representative GFP positive fluorescent cell and manually define its shape. To do so, click on "Estimate" and draw the border of the cell using the freehand selection tool. In this way the diameter and intensity threshold of the cell are automatically retained by the software.
  3. Click on "Find cells" to allow the software to localize transfected cells throughout the cortex. Then, if needed, manually remove false positives.
  4. Divide the whole thickness of the cortex into 8 areas of interest normalized in individual sections. To achieve this, click on "Region Tool", select 8 "Region Stripes" where the first (1) and the last (8) stripes correspond to the VZ and to the top of CP respectively. Click on "Apply" to allow the software to count the relative position of GFP transfected cells in the whole cortex. Finally click on "Save Quantification" to export data in an Excel file for the analysis.

Access restricted. Please log in or start a trial to view this content.

Results

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The experimental strategy designed to identify novel MCD causative genes is recapitulated in Figure 1.

By performing array-CGH in a cohort of 155 patients with developmental brain abnormalities variably combining PNH (Figure 2A), corpus callosum dysgenesis, colpocephaly, cerebellar hypoplasia and polymicrogyria associated with epilepsy, ataxia and cognitive impairment, we identified a 1.2 Mb min...

Access restricted. Please log in or start a trial to view this content.

Discussion

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

MCDs are important causes of intellectual disability and account for 20-40% of drug-resistant childhood epilepsy1,2. Interest in MCDs has increased dramatically over the past decade as a result of two major factors. The first is the improvement in brain imaging (particularly MRI), which allows physicians and scientists to visualize many brain malformations that were not previously recognized. The other is the evolution of genetic tools that have allowed the ident...

Access restricted. Please log in or start a trial to view this content.

Disclosures

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

The authors have nothing to disclose.

Acknowledgements

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,

We thank Dr. G. McGillivray, Pr. J. Clayton-Smith, Pr. W.B. Dobyns, Pr. P. Striano, Pr. I.E. Scheffer, Pr. S.P. Roberston and Pr. S.F. Berkovic for providing MCD patients. We thank Dr. F. Michel and D. Mei for technical advices and help. This work was supported by funding from the Seven Framework Programme of the EU, DESIRE project, contract number: Health-F2-602531-2013, (to V.C., R.G., A.R., A.F. and C.C.), INSERM (to A.R. and C.C.), Fondation Jérôme Lejeune (R13083AA to A.F, E.P.P and C.C) and Région Provence Alpes Côte d'Azur (APO2014 - DEMOTIC to C.C. and A.A.D). D.A.K is an EMBO Young Investigator and is supported by FWF grants (I914 and P24367).

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Picospritzer IIIParker Hannifin CorpP/N 051-0500-900Intracellular Microinjection Dispense Systems
Fast Green FCFSigma-AldrichF7252Fast green allow visual monitoring of the injection
BTX ECM 830 electroporatorBTX Harvard Apparatus45-0002The ECM 830 is a Square Wave Pulse generator designed for in vitro and in vivo applications
Microtome HM 650 VMicrom10076838Microtome HM 650 V vibratome 240V 50/60Hz with vibrating blade
FluoView 300OlympusThe Olympus FluoViewTM 300 is a point-scanning, point-detection, confocal laser scanning microscope designed for biology research application
eCELLence softwareGlance Vision TechnologieseCELLence is software designed for the quantitive analysis of cell migration
Agilent Microarray Scanner BundleArray slides
for 1 x 244K, 2 x 105K, 4 x 44K or 8 x 15KAgilentAgilent p/n G4900DA, G2565CA or G2565BA
for 1 x 1M, 2 x 400K, 4 x 180K or 8 x 60KAgilentAgilent p/n G4900DA or G2565CA
Hybridization Chamber, stainlessAgilentAgilent p/n G2534AChamber for array CGH hybridization
Hybridization Chamber gasket slides, 5-packGasket for array CGH hybridization
for 1-pack microarrays orAgilentAgilent p/n G2534-60003
for 2-pack microarrays orAgilentAgilent p/n G2534-60002
for 4-pack microarrays orAgilentAgilent p/n G2534-60011
for 8-pack microarraysAgilentAgilent p/n G2534-60014
Hybridization ovenAgilentAgilent p/n G2545A
Hybridization oven rotator for Agilent Microarray Hybridization ChambersAgilentAgilent p/n G2530-60029
Thermal cycler with heated lidAgilentAgilent p/n G8800A or equivalentTermal cycler for incubations
1.5 mL RNase-free Microfuge TubeAmbionp/n AM12400 or equivalentMicrocentrifuge
Magnetic stir barCorningp/n 401435 or equivalentInstrument for stirring
Qubit FluorometerLife Technologiesp/n Q32857Instrument for DNA quantification
Qubit dsDNA BR Assay Kit, for use with the Qubit fluorometerInvitrogenp/n Q32850Kit for Qubit fluorometer
UV-VIS spectrophotometerThermo ScientificNanoDrop 8000 or 2000, or equivalentInstrument for DNA quantification
P10, P20, P200 and P1000 pipettesPipetman or equivalentDNA dispensation
Vacuum ConcentratorThermo Scientificp/n DNA120-115 or
equivalent
Instrument to concentrate DNA
SureTag Complete DNA Labeling KitAgilentp/n 5190-4240DNA Labeling Kit (for Human Samples)
Purification Columns (50 units)Agilentp/n 5190-3391DNA Labeling Kit (for Human Samples)
AutoScreen A, 96-well platesGE Healthcarep/n 25-9005-98DNA Labeling Kit (for Human Samples)
GenElute PCR Clean-Up KitSigma-Aldrichp/n NA1020DNA Labeling Kit (for Human Samples)
Human Genomic DNAp/n G1521DNA Labeling Kit (for Human Samples)
For CGH microarrays:Promega(female) or p/n G1471 (male)Array CGH control DNA
For CGH+SNP microarrays:Coriellp/n NA18507, NA18517, NA12891, NA12878, or NA18579Array CGH control DNA
Oligo aCGH/ChIP-on-chip Wash Buffer Kit orAgilentp/n 5188-5226Array CGH hybridization and wash
Oligo aCGH/ChIP-on-chip Wash Buffer 1 andAgilentp/n 5188-5221Array CGH hybridization and wash
Oligo aCGH/ChIP-on-chip Wash Buffer 2Agilentp/n 5188-5222Array CGH hybridization and wash
Stabilization and Drying SolutionAgilentp/n 5185-5979Array CGH hybridization and wash
Oligo aCGH/ChIP-on-chip Hybridization KitAgilentp/n 5188-5220 (25) or p/n 5188-5380 (100)Array CGH hybridization and wash
Human Cot-1 DNAAgilentp/n 5190-3393Array CGH hybridization and wash
Agilent C scannerAgilentScanner for array CGH slides
SureSelect XT2 Reagent KitKit for target enrichment
HiSeq platform (HSQ), 16 SamplesAgilentp/n G9621A
HiSeq platform (HSQ), 96 SamplesAgilentp/n G9621B
HiSeq platform (HSQ), 480 SamplesAgilentp/n G9621C
MiSeq platform (MSQ), 16 SamplesAgilentp/n G9622A
MiSeq platform (MSQ), 96 SamplesAgilentp/n G9622B
MiSeq platform (MSQ), 480 SamplesAgilentp/n G9622C
DNA 1000 KitAgilentp/n 5067-1504Kit for the separation, sizing and quantification of dsDNA fragments from 25 to 1000 bp.
High Sensitivity DNA KitAgilentp/n 5067-4626Kit for analysis of fragmented DNA or DNA libraries.
AMPure XP KitKit for automated PCR purification.
5 mLAgencourtp/n A63880
60 mLAgencourtp/n A63881
450 mLAgencourtp/n A63882
Dynabeads MyOne Streptavidin T1Isolation and handling of biotinylated nucleic acids
2 mLLife TechnologiesCat #65601
10 mLLife TechnologiesCat #65602
Quant-iT dsDNA BR Assay Kit, for the Qubit fluorometerDNA quantification
100 assays, 2-1000 ngLife TechnologiesCat #Q32850
500 assays, 2-1000 ngLife TechnologiesCat #Q32853
Qubit assay tubesLife Technologiesp/n Q32856DNA quantification
SureSelec tXT2 Capture LibrariesAgilentdepending on the experimentKit for libraries capture
SureCycler 8800 Thermal CyclerAgilentp/n G8800ADNA amplification
96 well plate module for SureCycler 8800 Thermal CyclerAgilentp/n G8810ADNA amplification
SureCycler 8800-compatible 96-well platesAgilentp/n 410088DNA amplification
Optical strip capsAgilentp/n 401425DNA amplification
Tube cap strips, domedAgilentp/n 410096DNA amplification
Compression matsAgilentp/n 410187DNA amplification
2100 Bioanalyzer Laptop BundleAgilentp/n G2943CADNA amplification
2100 Bioanalyzer Electrophoresis SetAgilentp/n G2947CADNA amplification
Covaris Sample Preparation System, E-series or S-seriesCovarisDNA shearing
Covaris sample holdersp/n 520078DNA shearing
Nutator plate mixerBD Diagnosticsp/n 421105 or equivalentPlate Mixer
GaIIxIlluminanext generation sequencing machine

References

Loading...
$$\rightleftharpoonup{xx}$$ $$\longleftharp{xx}$$, $$\longrightharp{xx}$$,
  1. Meencke, H. J., Veith, G. Migration disturbances in epilepsy. Epilepsy Res. 9, 31-39 (1992).
  2. Shorvon, S., Stefan, H. Overview of the safety of newer antiepileptic drugs. Epilepsia. 38 (1), 45-51 (1997).
  3. Parrini, E., et al. Periventricular heterotopia: phenotypic heterogeneity and correlation with Filamin A mutations. Brain. 129 (7), 1892-1906 (2006).
  4. Fox, J. W., et al. Mutations in filamin 1 prevent migration of cerebral cortical neurons in human periventricular heterotopia. Neuron. 21 (6), 1315-1325 (1998).
  5. Sheen, V. L., et al. Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nat Genet. 36 (1), 69-76 (2004).
  6. Cappello, S., et al. Mutations in genes encoding the cadherin receptor-ligand pair DCHS1 and FAT4 disrupt cerebral cortical development. Nat Genet. 45 (11), 1300-1308 (2013).
  7. Moro, F., et al. Periventricular heterotopia in fragile X syndrome. Neurology. 67 (4), 713-715 (2006).
  8. Ferland, R. J., Gaitanis, J. N., Apse, K., Tantravahi, U., Walsh, C. A., Sheen, V. L. Periventricular nodular heterotopia and Williams syndrome. Am J Med Genet A. 140 (12), 1305-1311 (2006).
  9. van Kogelenberg, M., et al. Periventricular heterotopia in common microdeletion syndromes. Mol Syndromol. 1 (1), 35-41 (2010).
  10. Sheen, V. L., et al. Periventricular heterotopia associated with chromosome 5p anomalies. Neurology. 60 (6), 1033-1036 (2003).
  11. Neal, J., Apse, K., Sahin, M., Walsh, C. A., Sheen, V. L. Deletion of chromosome 1p36 is associated with periventricular nodular heterotopia. Am J Med Genet A. 140 (15), 1692-1695 (2006).
  12. Cardoso, C., et al. Periventricular heterotopia, mental retardation, and epilepsy associated with 5q14.3-q15 deletion. Neurology. 72 (9), 784-792 (2009).
  13. Cellini, E., et al. Periventricular heterotopia with white matter abnormalities associated with 6p25 deletion. Am J Med Genet A. 158 (7), 1793-1797 (2006).
  14. Bertini, V., De Vito, G., Costa, R., Simi, P., Valetto, A. Isolated 6q terminal deletions: an emerging new syndrome. Am J Med Genet A. 140 (1), 74-81 (2006).
  15. Dobyns, W. B., et al. Consistent chromosome abnormalities identify novel polymicrogyria loci in 1p36.3, 2p16.1-p23.1, 4q21.21-q22.1, 6q26-q27, and 21q2. Am J Med Genet A. 146 (13), 1637-1654 (2008).
  16. Conti, V., et al. Periventricular heterotopia in 6q terminal deletion syndrome: role of the C6orf70 gene. Brain. 136 (11), 3378-3394 (2013).
  17. Sheen, V. L., et al. Etiological heterogeneity of familial periventricular heterotopia and hydrocephalus. Brain Dev. 26 (5), 326-334 (2004).
  18. Jaglin, X. H., et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat. Genet. 41 (6), 746-752 (2009).
  19. Falace, A., et al. TBC1D24 regulates neuronal migration and maturation through modulation of the ARF6-dependent pathway. Proc Natl Acad Sci U S A. 111 (6), 2337-2342 (2014).
  20. Lunter, G., Goodson, M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res. 21 (6), 936-939 (2011).
  21. Pagnamenta, A. T., et al. Exome sequencing can detect pathogenic mosaic mutations present at low allele frequencies. J Hum Genet. 57 (1), 70-72 (2012).
  22. Yu, J. Y., DeRuiter, S. L., Turner, D. L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A. 99 (9), 6047-6052 (2002).
  23. Bai, J., et al. RNAi reveals doublecortin is required for radial migration in rat neocortex. Nat Neurosci. 6 (12), 1277-1283 (2003).
  24. Carabalona, A., et al. A glial origin for periventricular nodular heterotopia caused by impaired expression of Filamin-A. Hum Mol Genet. 21 (5), 1004-1017 (2012).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Cortical DevelopmentNeuronal MigrationPeriventricular Nodular HeterotopiaC6orf70 GeneConfocal MicroscopyQuantitative PCR

Related Articles